Moberg Pharma Annual Report for the abbreviated fiscal year January – June 2019

Report this content

Moberg Pharma´s Annual Report for the abbreviated fiscal year January – June 2019 has been published and is available on

About this information
Moberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out below, at 8.30 a.m. (CET) on September 27th 2019

For additional information, please contact:
Anna Ljung, VD, phone: +46 707 66 60 30, e-post:
Mark Beveridge, VP Finance, phone: +46 768 05 82 88, e-post:

About Moberg Pharma,
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company’s main asset, MOB-015, is a novel topical treatment for onychomycosis, for which phase 3 data in 800+ patients is expected in late 2019 in North America and the first half of 2020 in Europe. The pipeline also includes the late-stage asset BUPI for pain relief in oral mucositis. Clinical data generated for both assets indicate they have the potential to become market leaders in their respective niches. Moberg Pharma is headquartered in Stockholm and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB)